Please enter both email and password to log in
You need to upgrade your Flash Player
|
You need to upgrade your Flash Player to view this content.
What's New?
Your opinion requested!

|
Clinical Insights® in Lipid Management Issue 12 now available
Co-Editor and CCMD Education Council Member Peter Libby, MD, comments on results from the ENHANCE trial. Also featured: lipoprotein(a) levels are continuously associated with future CHD risk; very high levels of HDL-C and very large HDL particle size are associated with increased CV risk.
|
New CME-certified case study now live!
CCMD Faculty Member James M. McKenney, PharmD, presents a case exploring the assessment and management of a patient with atherogenic dyslipidemia. Upon completion of the evaluation form, you'll earn 0.75 AMA PRA Category 1 Credit™ instantly!
|
CMDManagement™ Summer 2008 issue now available for CME credit!
This issue of our award-winning newsletter explores the benefits of lipid-lowering therapies beyond LDL-C lowering. Also featured: a case study from CCMD Faculty Member Peter H. Jones, MD, exploring the management of a patient with evidence of subclinical atherosclerosis, and a patient handout focusing on prevention of coronary artery disease.
|
The latest in clinical literature
New selections: The association between physical activity and cardiovascular event risk, featuring expert commentary from CCMD Faculty Member Ezra A. Amsterdam, MD; baseline characteristics of participants in JUPITER; impact of the metabolic syndrome on macro- and microvascular outcomes in type 2 diabetes in UKPDS; and much more.
|
New slides in the Dynamic Slide Library
Visit our expanding library to view and download 11 new slides focusing on data from recent clinical trials, including ASTEROID, JUPITER, METEOR, ENHANCE, and SEACOAST.
|
New drug treatment table for hypertension
Read and download this new table that organizes various pharmacologic treatment options for hypertension, including diuretics, adrenergic inhibitors, alpha- and beta-blockers, direct vasodilators, calcium channel blockers, ACE inhibitors, ARBs, and more.
|
FDA Alert: Simvastatin With Amiodarone Increases Risk of Rhabdomyolysis
On August 8 ,2008, the FDA released a warning regarding reports of increased rhabdomyolysis risk from concomitant use of simvastatin greater than 20 mg qd and amiodarone, an arrhythmia treatment for controlling life-threatening recurrent ventricular arrhythmias. In its alert, the FDA noted that all statins have a potential risk of rhabdomyolysis, whether or not they are administered with amiodarone, but the risk is more prominent when used with the arrhythmia agent.
|
|
|
CCMD Co-Chairmen
|
Education Council
George L. Bakris, MD
|
Elizabeth Barrett-Connor, MD
|
Keith C. Ferdinand, MD
|
JoAnne M. Foody, MD
|
Peter Ganz, MD
|
Philip B. Gorelick, MD, MPH
|
Scott M. Grundy, MD, PhD
|
Steven M. Haffner, MD
|
Ronald M. Krauss, MD
|
John C. LaRosa, MD
|
Peter Libby, MD
|
Thomas A. Pearson, MD, MPH, PhD
|
|
|